Sterilization decision signals in drug development are unusual in one respect: the decision happens roughly once per programme, it is made by a small group, and if you are not in the conversation when it happens you wait years for the next one.
A marketing lead at a sterilization equipment manufacturer described the job exactly: "this is a business of finding a company that's at the right stage of their development where they're ready to make a sterilization decision."
That is a list-building problem, not a monitoring problem. You are not watching two hundred accounts for weekly movement. You are trying to assemble the set of programmes that will face a sterilization or packaging decision in the next eighteen months.
Where sterilization sits on the timeline
The decision clusters around the transition from early clinical work to scaled manufacture.
In discovery and preclinical, material is produced in small quantities and sterility is handled ad hoc. Somewhere between Phase 1 and Phase 2, a company producing a parenteral or a combination product has to commit to a sterilization method, because the method affects stability, the container closure system, the regulatory filing and the cost per unit for the life of the product.
That commitment is hard to reverse. Changing sterilization method after a pivotal trial means comparability work and regulatory consequences that most sponsors will not accept. So the window is real, it is narrow, and it sits earlier than most suppliers work.
Finding the programmes in your format
The buying criterion here is delivery format. Not the disease, not the company size. The same marketing lead put it this way: not everybody developing a cancer drug, but everybody developing a product delivered in a particular format, with a particular framework, that is a biologic.
Format is rarely a field you can select directly, because it is often not recorded as structured data in the first place. What works instead is a combination of filters that lands you on substantially the same set:
| Filter | Why it proxies for format | What it misses |
|---|---|---|
| Modality (biologics, cell, gene) | Biologics are overwhelmingly parenteral, so format questions are live | Small-molecule injectables |
| Phase 1 and 2 | The window when the decision is made | Programmes that decided early |
| Therapeutic area | Some areas map tightly to formats, such as ophthalmology to intravitreal | Broad areas with mixed formats |
| Saved search | New programmes appear as they register | Nothing, this is the part that works well |
Ophthalmology is the clearest case of the therapeutic-area proxy working: the delivery route is largely determined by the anatomy, so filtering the area gets you close to filtering the format. Oncology is the clearest case of it working less well, because the same indication spans oral agents, infusions and implants.
Build the combination once, save it, and give the resulting list a short human pass. Twenty minutes reviewing eighty companies is a good trade for a list that then maintains itself.
Biologics versus small molecule
The split matters more here than almost anywhere else in life-sciences selling.
Biologics are heat-sensitive, which rules out several conventional sterilization approaches and makes the method question consequential and early. Small molecules are more robust, the decision is often more routine, and the supplier conversation is more price-driven.
If your equipment addresses the biologics constraint, the modality filter is doing most of your qualification for you, and that is the single highest-value filter available today.
Regulatory precursors
Three public sources sit outside trial registries and are worth checking on named accounts:
Device registry listings. For combination products, unique device identifier records carry sterilization method. This is a verification source rather than a discovery source: useful once you have a company, not a way to find one.
510(k) and equivalent submissions. For device-led programmes, the submission indicates a company approaching commercialisation with sterilization decided or being decided.
CMC and manufacturing hires. A company posting for a head of manufacturing or a CMC lead is building the function that will own the decision. This is often the earliest visible signal of all.
See Salesmotion on a real account
Book a 15-minute demo and see how your team saves hours on account research.
Building a list that refreshes
The mechanic worth setting up, once:
- Define the criteria you can actually filter on: modality, phase, therapeutic area.
- Save it as a search so new registrations appear without anyone re-running it.
- Review weekly, not daily. This is a slow-moving segment and daily review trains people to ignore the list.
- Keep a dismissal record. A programme you rejected in March because it was too early is exactly the one to revisit in December.
Frequently asked questions
How do I narrow to my delivery format? Combine modality, phase and therapeutic area, then save the search so it refreshes as new programmes register. For a parenteral biologics focus, modality plus Phase 1 and 2 does most of the work. Bring your actual criteria to a call and we will build the combination with you.
Do you cover combination products? Yes, where they appear in trial registries and regulatory filings, as part of the sponsor record. You reach them through the modality and therapeutic-area route described above.
How far ahead should I be prospecting? Aim at Phase 1 and early Phase 2. By late Phase 2 the method is usually settled and changing it carries regulatory cost the sponsor will not absorb.
Is this a monitoring product or a list-building product for us? List building, primarily. If you close a small number of high-value decisions a year, the value is a maintained universe of programmes at the right stage rather than a daily alert feed.
If you want to see what your programme universe looks like on your actual format criteria, that is worth half an hour on real records. See how it works for device and sterilization suppliers.
